When entering the unknown world of watching your child slip slowly on to the path that leads towards death and the finality of non-existence, there is little comfort to be found, particularly if you are an atheist. Consequently, any support that can be identified, which enables you to go on and face each day, making the most of every moment that your son or daughter is still with you, becomes a lifeline.
For our family, such support came in the form of the paediatric outreach nursing team (PONT) from our local hospital (Kingston). This is a team of nurses who, as the title suggests, visit families in the community, providing certain nursing services for sick children. This means that families do not have to journey to hospital every time they need for example a dressing changed or a line flushed. The nurses work around the family’s schedule. They disrupt family routine as little as possible, fitting in with your convenience, rather than expecting you to fit in with theirs. This is in great contrast to the experience of being in hospital, where almost everything seems to be done at the hospital’s convenience and patients can wait endlessly, with no apology given. In other words, the PONT service is family-centred and providers of other hospital services could learn a huge amount from them.
I cannot stress enough the value of this service to families like ours. The PONT figured in our lives from the beginning of George’s treatment – changing dressings, flushing lines, offering help and advice – but it was during the final stages of our son’s cancer that their presence became invaluable.
Tuesday, 10 January 2012
An Invaluable Service by Irene Pantziarka
TP53 Forum Now Open
We have previously mentioned the founding of the George Pantziarka TP53 Trust, the first group in the UK dedicated to Li Fraumeni Syndrome (LFS) and other TP53 disorders. The trust is named in honour of my son, George, who passed away in April 2011 after battling with his third cancer, an osteosarcoma of the mandible. The work to set up the charity is proceeding, and I am pleased to announce that the website for the trust is now live at:
Part of the site is the forum, which is we hope will become central to the trust. If you or your family are affected by Li Fraumeni Syndrome or other TP53 disorder please visit the forum, register and introduce yourselves. As a community people with LFS and other TP53 disorders are isolated and underserved, together we can work to change that.
Monday, 9 January 2012
Q&A With Dr Stefano Fais - PPI and Cancer
In a previous article I highlighted some recent results of the work of Dr Stefano Fais and his colleagues in using the over the counter gastric acid treatment lansoprazole to stop tumours becoming resistant to chemotherapy. Lansoprazole is one of a family of drugs called proton pump inhibitors (PPI), that are targeted at highly acidic environments in the body - and tumours, as is well known, create very highly acidic microenvironments. As chemo-resistance is a major problem in oncology, leading to treatment failure in many patients, this is important work. Kindly Dr Fais has agreed to answer a few questions for anticancer.org.uk:
PP: Why is it important to focus on the tumour microenvironment?
SF: Because malignant cells are progressively selected within the tumor mass for their ability to survive in a very hostile microenvironment, an environment that is generated by their own metabolism. In fact, in the same microenvironment either normal cells or more differentiated cells usually die. Tumor cells survive thanks to some mechanisms them to quickly eliminate toxins, which would otherwise be able to kill them if they were free to accumulate.
PP: What has been the pre-clinical experience with PPI treatment and cancer in people?
SF: Proton pump inhibitors actually block a mechanism that on one hand induces acidification of extracellular environment, in turn impairing both the body’s reaction to the tumor and also highly reducing the efficacy of drugs that are neutralized by the acidic microenvironment. In fact, pre-clinical data have shown that PPI can increase the efficacy of current anti-tumor therapies and induce a real anti-tumor effect by depriving tumor cells of a key survival mechanism.
PP: Why is it important to focus on the tumour microenvironment?
SF: Because malignant cells are progressively selected within the tumor mass for their ability to survive in a very hostile microenvironment, an environment that is generated by their own metabolism. In fact, in the same microenvironment either normal cells or more differentiated cells usually die. Tumor cells survive thanks to some mechanisms them to quickly eliminate toxins, which would otherwise be able to kill them if they were free to accumulate.
PP: What has been the pre-clinical experience with PPI treatment and cancer in people?
SF: Proton pump inhibitors actually block a mechanism that on one hand induces acidification of extracellular environment, in turn impairing both the body’s reaction to the tumor and also highly reducing the efficacy of drugs that are neutralized by the acidic microenvironment. In fact, pre-clinical data have shown that PPI can increase the efficacy of current anti-tumor therapies and induce a real anti-tumor effect by depriving tumor cells of a key survival mechanism.
Wednesday, 4 January 2012
Lansoprazole and resistance to chemotherapy
For this first post of 2012 I want to start on a positive note by highlighting an interesting and relevant piece of research from Italy. Chemoresistance is the term used to describe the process whereby cancer cells become resistant to chemotherapy. Unfortunately this is a serious and widespread problem, right across the spectrum of cancer types. Tumours that regress quickly from the initial rounds of chemo, sometimes shrinking away to nothing almost, suddenly seem to bounce back, growing again and shrugging off repeated rounds of the chemo that seemed to knock them out. In many cases these resistant cancer cells become ‘multi-drug resistant’, which means that second and third line chemotherapy treatments also have little or no effect. So, finding a way of reversing this resistance is an important aim in cancer research, and one which is clinically relevant across most kinds of cancer.
It’s this problem that a team of researchers and clinicians in Italy have tackled in a clinical trial. Building on work previously done in the laboratory, Stefano Fais and his co-workers carried out a clinical trial on cats and dogs (now called ‘companion animals’ rather than pets!) with cancers that were resistant to standard chemotherapy. Don’t for one minute think that because the patients were animals that this is not relevant research. Cancers in cats and dogs are much closer to human cancers than cancers in rats and mice. In some types of disease, such as osteosarcoma, the disease acts in exactly the same way that it does in people, and is treated with the same drugs and treatments.
These animals were treated with the common anti-acid drug lansoprazole at high doses – a drug that is available over the counter in the UK – along with the chemotherapy drugs that often fail due to the development of chemoresistance. The response of these animals was compared to another set of animals that had the conventional chemo-only treatment (it was the owners of the animals who decided to stick to the conventional treatments only).
The results were very clear. In the lansoprazole treated group, more than two thirds of animals showed partial or complete responses, compared to 17%of animals in the chemo-only group who showed short-lived partial responses. What’s more, even in the non-responders in the lansoprazole group, the owners of the animals indicated that their pets showed improved quality of life – less pain, less weight loss, greater agility etc.
Tuesday, 20 December 2011
Coley's Toxins In The UK
Coley's Toxins is an cancer therapy from the pre-history of modern oncology. Developed by surgeon William Coley at the end of the 19th century, this was a treatment that showed some impressive results against a range of hard to treat cancers - especially sarcomas. Coley began the treatment after noticing that some patients with cancer experienced tumour regression after becoming infected in hospital. These rare cases of spontaneous remission were regarded as miracles, which they still are, pretty much. The infected patients would develop severe fevers, chills, aches and pains and the rest of the signs of a massive immune response that ended with the tumours being attacked by the immune system.
Coley took this idea forward and developed a treatment that consisted in inducing this severe immune response by injecting bacterial material into his patients. The patients reacted to this injection of 'bacterial toxins' by developing the feverish response as their immune systems kicked in. And, in some cases, the resulting immune response did indeed lead to the tumours being attacked and ultimately disappearing. This did not happen in all patients, but it happened at a rate that is comparable to some of the more modern cancer treatments. And, it must be said, because the tumours were cleared by the immune system, there were none of the long-term side-effects you get from chemotherapy or radiotherapy, and in many of those individuals where the tumours disappeared the treatment really did lead to a cure.
However, with the advent of radiotherapy, chemotherapy and advances in surgery, Coley's treatment fell by the way-side. Coley is often credited with being the 'grandfather' of cancer immunotherapy, but largely his treatment barely exists as a historical footnote in oncology. There is still a fair degree of interest in it from those interested in alternatives, but in the mainstream of medicine Coley's toxins are dead.
Coley took this idea forward and developed a treatment that consisted in inducing this severe immune response by injecting bacterial material into his patients. The patients reacted to this injection of 'bacterial toxins' by developing the feverish response as their immune systems kicked in. And, in some cases, the resulting immune response did indeed lead to the tumours being attacked and ultimately disappearing. This did not happen in all patients, but it happened at a rate that is comparable to some of the more modern cancer treatments. And, it must be said, because the tumours were cleared by the immune system, there were none of the long-term side-effects you get from chemotherapy or radiotherapy, and in many of those individuals where the tumours disappeared the treatment really did lead to a cure.
However, with the advent of radiotherapy, chemotherapy and advances in surgery, Coley's treatment fell by the way-side. Coley is often credited with being the 'grandfather' of cancer immunotherapy, but largely his treatment barely exists as a historical footnote in oncology. There is still a fair degree of interest in it from those interested in alternatives, but in the mainstream of medicine Coley's toxins are dead.
Monday, 19 December 2011
Curcumin Trial In The UK
One of the nice things about the ClinicalTrials.gov website, (which I have discussed previously here: http://www.anticancer.org.uk/2011/08/searching-for-clinical-trials.html), is that it lets you set up RSS feeds based on yor own search criteria. It's through this mechanism that I've learned about a new clinical trial for cancer using curcumin. What's more, this new trial is based in the UK, which is welcome since most curcumin trials have been in the US and other countries.
As with many of the current trials of curcumin, this one uses it as an adjunct to conventional chemotherapy. Specifically this is a trial aimed at patients with inoperable colorectal liver metastases who will be commencing standard oxaliplatin-based (FOLFOX) chemotherapy, In addition to their normal chemotherapy, patients will be given oral curcumin tablets (curcumin C3 complex, to be exact). In the first phase of the trial the aim is to test the safety and tolerability of curcumin and FOLFOX, with doses of up to 4g per day of curcumin. In the second phase of the trial patients will be randomised and some will received FOLFOX and curcumin, and some will just have the standard FOLFOX treatment.
In many respects this trial is treading familiar ground - curcumin has been trialled as an adjunct to other chemotherapy treatments for other cancers. One example that springs to mind are the trials of curcumin and gemcitabine for advanced pancreatic cancer. In one such trial 4g doses of curcumin were tried, but patients found it hard to take the volume of tablets, in another trial patients took up to 8g of curcumin without problem.
While there's a lot of excitement about curcumin as a cancer treatment, it's fairly clear by now that it is not a viable therapy on its own as things stand. The future of curcumin as a cancer treatment lies in two directions. The first as a support to existing treatments - which is what this trial is looking at. Curcumin may blunt some of the side effects of chemotherapy and radiotherapy, may make these treatments work better and may reverse drug resistance in some tumours.
The other path for curcumin lies in new formulations. This is an area of intense activity at the moment. In some cases scientists are working to improve the bioavailability of curcumin through using liposomes or other technologies. These new formulations take curcumin and simply make it more available to the body, particularly to tumour cells. A different approach is to take curcumin as a starting point and to alter the chemical structure to create new drugs that are based on it. These new drugs are more potent than curcumin and the hope is that they will be more powerful anti-cancer agents.
Both these approaches have merit, but for now it's good to see that curcumin is being tried in trials now.
To find out more about this this trial take a look here: http://clinicaltrials.gov/ct2/show/NCT01490996
As with many of the current trials of curcumin, this one uses it as an adjunct to conventional chemotherapy. Specifically this is a trial aimed at patients with inoperable colorectal liver metastases who will be commencing standard oxaliplatin-based (FOLFOX) chemotherapy, In addition to their normal chemotherapy, patients will be given oral curcumin tablets (curcumin C3 complex, to be exact). In the first phase of the trial the aim is to test the safety and tolerability of curcumin and FOLFOX, with doses of up to 4g per day of curcumin. In the second phase of the trial patients will be randomised and some will received FOLFOX and curcumin, and some will just have the standard FOLFOX treatment.
In many respects this trial is treading familiar ground - curcumin has been trialled as an adjunct to other chemotherapy treatments for other cancers. One example that springs to mind are the trials of curcumin and gemcitabine for advanced pancreatic cancer. In one such trial 4g doses of curcumin were tried, but patients found it hard to take the volume of tablets, in another trial patients took up to 8g of curcumin without problem.
While there's a lot of excitement about curcumin as a cancer treatment, it's fairly clear by now that it is not a viable therapy on its own as things stand. The future of curcumin as a cancer treatment lies in two directions. The first as a support to existing treatments - which is what this trial is looking at. Curcumin may blunt some of the side effects of chemotherapy and radiotherapy, may make these treatments work better and may reverse drug resistance in some tumours.
The other path for curcumin lies in new formulations. This is an area of intense activity at the moment. In some cases scientists are working to improve the bioavailability of curcumin through using liposomes or other technologies. These new formulations take curcumin and simply make it more available to the body, particularly to tumour cells. A different approach is to take curcumin as a starting point and to alter the chemical structure to create new drugs that are based on it. These new drugs are more potent than curcumin and the hope is that they will be more powerful anti-cancer agents.
Both these approaches have merit, but for now it's good to see that curcumin is being tried in trials now.
To find out more about this this trial take a look here: http://clinicaltrials.gov/ct2/show/NCT01490996
Comment Spam
One of the things I've discovered since starting this blog, is that there are some people for whom no website, forum or blog cannot be exploited for gain. This site encourages comments from readers, but it has to be said that there aren't many comments being published. It's a shame, but I guess that some people just want to read and not write. The fact that traffic is increasing and that many of the visitors are being referred here via other blogs, Facebook and other social media is positive.
But comments are being left here that I'm not publishing.
This site uses comment moderation - comments have to be approved before being published - and it's a good thing too. Everyday there are comments left here which are really just 'comment spam'. The comments contain some innocuous are often barely literate text - 'this is a good useful nice site, for sharing' - along with a link to another site. Usually the link leads to some company selling something cancer-related: supplements, nursing care, clinics etc.
I think it's really low to try and exploit an anti-cancer site like this - have these people got no conscience?
But comments are being left here that I'm not publishing.
This site uses comment moderation - comments have to be approved before being published - and it's a good thing too. Everyday there are comments left here which are really just 'comment spam'. The comments contain some innocuous are often barely literate text - 'this is a good useful nice site, for sharing' - along with a link to another site. Usually the link leads to some company selling something cancer-related: supplements, nursing care, clinics etc.
I think it's really low to try and exploit an anti-cancer site like this - have these people got no conscience?
Subscribe to:
Posts (Atom)